Stay updated on Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial page.

Latest updates to the Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial page
- Check5 days agoChange DetectedA sitewide banner announces an NIH transition update, including a notice about using “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check12 days agoChange DetectedThe footer revision number changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check19 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check40 days agoChange DetectedThe study record page now displays a 403 Forbidden error, replacing the previous detailed content. The detailed study information and related navigation are effectively hidden behind an access-block page.SummaryDifference16%

- Check47 days agoChange DetectedThe website_changes section shows no additions or deletions, indicating the page content remains the same according to the supplied data.SummaryDifference0.0%

- Check54 days agoChange DetectedA new study site was added in Sfax, Tunisia (1053), expanding enrollment options. The prior Tunisia site entry (1053) was removed.SummaryDifference0.4%

Stay in the know with updates to Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial page.